BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Tyrosine Pharma Changes Name To Zocere, Inc.


1/16/2014 9:37:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Albuquerque, N.M., January 16, 2014 - - Tyrosine Pharma, Inc., a New Mexico-based pharmaceutical company, has changed its name to Zocere, Inc. The shift in nomenclature reflects the company’s focus on expanding its portfolio of injectable, neuro-protectant drugs.

Commenting on the name change, Zocere President and CEO Wayne Laslie said there are few treatment options for neurological trauma, particularly stroke, which translates into an opportunity for new and novel therapeutic solutions.

“We all know someone who has been struck down by stroke and how frustrating it is for physicians and family members to have so few treatment options. Zocere is working to change that by developing injectable, brain protecting drugs that have the potential to reduce deaths, long-term disability and the financial impact of stroke,” said Laslie.

The development of neuro-protection drugs is badly needed. Stroke is the second leading cause of death worldwide and number one cause of long-term disability. The financial impact of stroke is also significant; in 2010 alone, the cost of health care, medications, and missed work to the U.S. economy was $73.7 billion. Current treatment options for blood clot-induced ischemic stroke—which account for 87 percent of strokes—are limited and little used.

Zocere is licensing a STEP peptide from STC.UNM developed at the University of New Mexico and is developing an injectable drug designed to protect patients from brain injury by arresting the progression of brain damage caused by reduced blood flow. While the initial target is stroke, the drug shows promise in treating other brain trauma such as concussion.

About Zocere, Inc.

Headquartered in Albuquerque, New Mexico, Zocere, Inc., is a startup pharmaceutical company developing injectable, neuro-protectant drugs intended to combat stroke and other neurological trauma. Zocere is led by a team of seasoned pharmaceutical industry executives with extensive experience in drug commercialization. Visit www.Zocere.com.

For More Information
Melanie Lux, 803.331.4794 mlux@luxandassociates.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES